BioXcel Therapeutics, Inc..
BTAI.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for neuroscience and immuno-oncology. The company's lead product candidate, BXCL501 (dexmedetomidine), is a sublingual film formulation for the acute treatment of agitation associated ...Show More
Better Health for All
-30
BioXcel Therapeutics' core business is developing medicines for unmet medical needs in neuroscience and immuno-oncology, including an approved drug for agitation (IGALMI) and candidates for Alzheimer's and cancer, indicating an entire business devoted to health improvement.
1
The company invested $8.7 million in R&D in Q3 2025, leveraging AI for drug discovery.
2
BioXcel also launched the 'Boiling Point' educational campaign to educate healthcare providers on agitation.
3
However, the company faces severe issues regarding safety and clinical trial ethics. In June 2023, BioXcel disclosed that a principal investigator at a late-stage trial site fabricated emails to conceal an adverse safety event, and an FDA inspection in December 2022 found failures to follow protocols, including consent forms and keeping adequate case histories.
4
Shareholders also alleged misrepresentation of a key clinical trial’s enrollment and completeness, with a federal judge finding investors adequately pleaded an inference that executives intended to deceive.
5
While the company's compliance manual outlines policies for patient assistance programs and safeguarding patient data, there is no evidence of their scale, effectiveness, or specific reach to vulnerable populations.
6
Similarly, support for patient organizations is mentioned, but without specific funding or reach data.
7
The company is exploring new indications for dexmedetomidine in chronic stress-related disorders, including opioid withdrawal and alcohol use disorder in patients with PTSD, which addresses addiction mitigation.
8
Fair Money & Economic Opportunity
0
BioXcel Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing medicines. The provided articles discuss its investigational medicines, a public offering, and a J-Code for one of its products. There is no evidence in the articles that the company engages in activities related to lending, insuring, moving, or storing money, nor does it offer financial services or products to consumers. As such, no specific, concrete data points relevant to the 'Fair Money & Economic Opportunity' value's KPIs are present. Therefore, all KPIs are omitted as per the scoring rules.
Fair Pay & Worker Respect
-20
BioXcel Therapeutics' employee overall rating is 2.7 out of 5 (54%), and their work satisfaction rating is 2.6 out of 5 (52%).
1
The company experienced a workforce reduction of 28% in 2024, laying off 15 out of approximately 54 employees.
2
There have been no significant labor law violations or fines in the past two years.
3
Health insurance is offered as an employee benefit, though a specific coverage percentage is not provided.
4
Fair Trade & Ethical Sourcing
0
No specific, quantitative evidence regarding BioXcel Therapeutics, Inc.'s fair trade and ethical sourcing practices, such as fair-trade certification share, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend, was found in the provided articles.
1
Honest & Fair Business
-50
The company has a whistleblower policy with a 24/7 anonymous hotline and a strict non-retaliation policy, as detailed in its Healthcare Compliance Manual and Code of Business Conduct and Ethics.
1
However, there is no explicit evidence of independent investigation processes for reports. The company committed to appoint a new independent board director,
2
and its Code of Business Conduct and Ethics requires board approval for transactions that could give rise to conflicts of interest involving directors or executive officers.
3
The anti-corruption policy is FCPA-compliant, prohibits bribes and kickbacks, and requires mandatory annual Trade Controls Compliance training for all employees.
4
However, the policy lacks specific effectiveness metrics. An independent third-party audit was conducted on data from a single site in the TRANQUILITY II Phase 3 trial, reviewing over 50% of subjects enrolled at that site with 95% confidence.
5
This audit found no evidence of misconduct or fraud beyond a previously reported instance and no findings impacting data integrity.
6
However, this audit was limited to a single trial site and does not represent company-wide third-party verification of ethical claims.
Kind to Animals
0
No specific, concrete data points were found in the provided articles regarding BTAI.US's performance on any of the 'Kind to Animals' KPIs. Information about general industry trends or regulatory changes, such as the FDA Modernization Act 2.0, was present but did not provide company-specific evidence of actions, policies, or quantitative metrics for BioXcel Therapeutics, Inc.
1
No War, No Weapons
-30
BioXcel Therapeutics' lead product candidate, BXCL501, is primarily developed for civilian applications such as agitation in bipolar disorders, schizophrenia, and Alzheimer's dementia.
1
However, the U.S. Department of Defense (DoD) has provided a $2.8 million grant to the University of North Carolina at Chapel Hill to study BXCL501 for acute stress disorder (ASD).
2
Additionally, other DoD-funded trials are underway for BXCL501 related to PTSD/alcohol use disorder and opioid use disorder.
3
This indicates an emphasis on civilian applications, but with incidental military use through specific, vetted research grants for conditions relevant to military personnel.
Planet-Friendly Business
0
The provided articles do not contain specific, quantitative data points for any of the 'Planet-Friendly Business' KPIs. While some articles mention overall ESG risk ratings or net impact scores from third-party models, these do not provide the concrete metrics required by the rubric, such such as total emissions, renewable energy percentages, water use per revenue, or details on specific environmental programs and their outcomes.
1
Therefore, no KPIs can be scored based on the available evidence.
Respect for Cultures & Communities
0
No evidence available to assess BioXcel Therapeutics, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess BioXcel Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No specific, quantitative data related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education was found in the provided articles. While one article mentions "Waste" as a negative impact category with a score of -0.56, this is a general impact score and does not provide the specific quantitative metrics required by the rubric's KPIs.
1